Hormonal
Semaglutide (2.4 mg weekly) produces significant weight loss (approx. 15%) by acting as a GLP-1 receptor agonist that stimulates satiety centers in the hypothalamus.
Semaglutide is a weekly injectable medication that mimics a gut hormone to signal fullness to the brain. Clinical trials show it can lead to roughly 15% body weight loss when combined with lifestyle changes, significantly outperforming lifestyle changes alone. It requires a prescription and ongoing medical supervision.
Semaglutide is an analog of human glucagon-like peptide-1 (GLP-1)... The mechanism of action of semaglutide involves both peripheral and central effects... In the central nervous system, semaglutide primarily acts on GLP-1 receptors located in the hypothalamus... Those treated with semaglutide achieved an average weight reduction of 14.9%...
Why this rating
Based on large, randomized, double-blind, placebo-controlled trials (STEP 1, STEP 3).
Source
TRENDS IN OBESITY TREATMENT: A REVIEW OF THE LITERATURE FROM THE LAST SIX YEARS
Adam Sobiński et al. · International Journal of Innovative Technologies in Social Science · 2025
DOI 10.31435/ijitss.4(48).2025.4326
More from this paper
- Tirzepatide (5-15 mg weekly) produces dose-dependent weight loss (up to 25.3%) by acting as a dual GLP-1 and GIP receptor agonist.Strong
- Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) are highly effective surgical interventions for severe obesity, with RYGB showing slightly greater long-term weight loss.Strong
- Intragastric balloons (Obalon, Orbera, ReShape Duo) provide temporary weight loss (12-25% EWL) when combined with lifestyle modifications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →